BANK OF MONTREAL /CAN/ - SORRENTO THERAPEUTICS INC ownership

SORRENTO THERAPEUTICS INC's ticker is SRNE and the CUSIP is 83587F202. A total of 225 filers reported holding SORRENTO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of SORRENTO THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$100,556
-23.2%
60,943
-2.5%
0.00%
Q3 2022$131,000
-76.2%
62,513
-76.3%
0.00%
Q2 2022$550,000
+157.0%
263,307
+211.3%
0.00%
Q1 2022$214,000
+275.4%
84,591
+614.1%
0.00%
Q4 2021$57,000
-45.7%
11,846
-11.8%
0.00%
Q3 2021$105,000
+4.0%
13,424
+32.0%
0.00%
Q2 2021$101,000
-90.1%
10,172
-92.3%
0.00%
Q1 2021$1,017,000
-44.2%
131,431
-48.2%
0.00%
-100.0%
Q4 2020$1,822,000
+557.8%
253,652
+869.7%
0.00%
Q3 2020$277,000
+17.9%
26,158
-13.7%
0.00%
Q2 2020$235,000
+7733.3%
30,304
+1830.2%
0.00%
Q1 2020$3,000
-94.8%
1,570
-91.0%
0.00%
Q4 2019$58,000
-84.6%
17,372
-90.1%
0.00%
Q3 2019$376,000
-53.2%
175,985
-41.5%
0.00%
-100.0%
Q2 2019$803,000
-41.9%
300,941
+3.4%
0.00%0.0%
Q1 2019$1,383,000
+3967.6%
291,161
+1925.2%
0.00%
Q4 2018$34,000
-97.5%
14,377
-95.3%
0.00%
-100.0%
Q3 2018$1,335,000
+12.3%
303,286
+83.7%
0.00%
+100.0%
Q2 2018$1,189,000
+59350.0%
165,070
+33725.8%
0.00%
Q1 2017$2,000
-33.3%
4880.0%0.00%
Q4 2016$3,000
-25.0%
4880.0%0.00%
Q3 2016$4,000
+33.3%
4880.0%0.00%
Q2 2016$3,0004880.00%
Other shareholders
SORRENTO THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 6,000,000$66,900,0002.57%
SABBY MANAGEMENT, LLC 606,298$6,760,0001.01%
Virtus ETF Advisers LLC 66,851$745,0000.39%
Newbridge Financial Services Group, Inc. 26,900$300,0000.30%
Avidian Wealth Solutions, LLC 330,000$3,680,0000.28%
Spectrum Wealth Advisory Group, LLC 36,692$422,0000.27%
COWEN AND COMPANY, LLC 129,200$1,441,0000.24%
Cormorant Asset Management, LP 500,000$5,575,0000.21%
SYMMETRY PEAK MANAGEMENT LLC 27,500$307,0000.20%
Aristides Capital LLC 24,302$271,0000.19%
View complete list of SORRENTO THERAPEUTICS INC shareholders